Biotech will cut 46 staff, mostly in research, including the entire antibody group, to focus on commercializing its Phase III thrombocytopenia candidate fostamatinib. Rigel adds industry vet Eldon Mayer to head up commercial team.
About two weeks after announcing success in the first Phase III trial of its platelet drug fostamatinib in chronic/persistent immune thrombocytopenia, Rigel Pharmaceuticals Inc. announced a 38% staff reduction, more or less gutting its R&D division to add a nearly equivalent headcount in commercial personnel.
As part of the Sept. 15 announcement, Rigel reported the retirement of board member and Executive VP of Discovery and...
The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.
The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.
Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?
